Quality Control: Linking Retrotranslocation and Degradation
Misfolded proteins in the ER require the p97 AAA ATPase for dislocation across the membrane prior to degradation by the cytosolic proteasome. The mechanism by which dislocated proteins are delivered to the proteasome from p97 is unclear, but recent studies suggest an important regulatory role for the protein ataxin-3. The fatal neurodegenerative Machado-Joseph disease, also known as spinocerebellar ataxia type 3, is caused by mutations of the polyglutamine-containing protein ataxin-3 [1] . The biochemical properties of ataxin-3 are well known, but its physiological role has been elusive. Two recent studies [2, 3] now implicate ataxin-3 in the process known as endoplasmicreticulum-associated degradation (ERAD), suggesting a link between endoplasmic reticulum (ER) stress and the neuropathology associated with disease. After targeting to the ER, proteins are screened by a quality control system to prevent misfolded forms from progressing through the secretory pathway. Rather than accumulating within the cell, these aberrant proteins are disposed of by ERAD. This requires the dislocation of such proteins across the ER membrane and their subsequent degradation by the cytosolic proteasome system. The precise nature of the membrane channel through which dislocation occurs is not yet known, but a number of proteins have been implicated, including Sec61, Derlin-1 and VIMP [4] . However, evidence suggests that the hexameric AAA ATPase p97/VCP (known as Cdc48 in yeast) plays an important role in driving the dislocation of a range of proteins [5] [6] [7] [8] . A complex comprising p97, and the adaptor proteins Ufd1 and Npl4, is recruited to the cytosolic face of the ER membrane, where it is believed to 'pull' dislocating polypeptides through the channel and into the cytosol.
During their dislocation, ERAD substrates are normally polyubiquitinated, and the p97 complex has been shown to bind directly to these polyubiquitin chains. A further set of polyubiquitin-binding proteins, including Rad23p and Dsk2p, are associated with the proteasome, where they function in the final delivery of the ERAD substrate to the degradation machinery [9] . The mechanism by which an ERAD substrate is transferred from the p97 complex to proteasomal polyubiquitin-binding proteins is not known. Previous studies have shown that ataxin-3 can interact with both p97/VCP and Rad23p [10, 11] , and two recent papers [2, 3] suggest that ataxin-3 is a critical link in this chain.
Wang et al. [2] and Zhong and Pittman [3] have studied the effects of the expression of wild-type and mutant forms of ataxin-3 on a range of ERAD substrates. Both studies confirm that full-length ataxin-3 binds directly to p97, but ataxin-3 was also found in a membrane-associated form that could be co-immunoprecipitated together with several other ERAD components, including Derlin-1, VIMP and the ER-specific ubiquitin ligase Hrd1p [2] . Previous studies have shown that ataxin-3 has three functional ubiquitin-interacting modules plus a deubiquitinating activity [12] [13] [14] [15] .
These new studies [2, 3] provide evidence that ataxin-3, and specifically its deubiquitinating activity, are required in ERAD. The ataxin-3 C14A mutant lacks the catalytic deubiquitinating activity but is still able to bind ubiquitinated substrates with high affinity. Ectopic expression of ataxin-3 C14A in transfected cells led to the accumulation of typical ERAD substrates, including TCRa, a membrane component of the T-cell receptor which is degraded in the absence of other T-cell receptor subunits. The accumulated forms of TCRa were found to be extensively polyubiquitinated in atx C14A cells, suggesting a role for ataxin-3 in the deubiquitination of substrate during the normal ERAD process.
This was further confirmed by the demonstration that p97-bound substrate could be deubiquitinated in vitro in the presence of wild-type ataxin-3 but not the C14A mutant. Consistent with this, Wang et al. [2] further demonstrated a dramatic increase in the amount of ubiquitinated proteins that could be co-immunoprecipitated with p97in ataxin-3 C14A cells compared to controls. Zhong and Pittman [3] further examined the effect of pathological mutations in the polyglutamine tract of ataxin-3. Their studies show that mutant ataxin-3 binds p97/VCP more avidly than the wild-type protein, and this correlates with decreased degradation of the ERAD substrate CD3d [3] . These studies suggest that the pathology of ataxin-3 mutants relates to defective ERAD.
Taken together, the new data [2, 3] indicate that ataxin-3 plays a critical role in the p97-associated degradation of ERAD substrates, and that this is necessary for the efficient release of substrate from the p97 dislocation machinery. Complete deubiquitination of substrate would prevent subsequent interaction with proteasomal polyubiquitin-binding proteins and so it is proposed that ataxin-3 might function as an 'editing enzyme' that merely shortens polyubiquitin chains. In this model the normal deubiquitinating activity of ataxin-3 would trim polyubiquitin chains to a level that allows their release from the p97 complex, but still permits binding to crucial proteasomal components.
Interestingly, the ubiquitin chains of ERAD substrates in Saccharomyces cerevisiae are progressively shortened as they transit to the proteasome [16] . Such a role for mammalian ataxin-3 would require tight regulation since any change in the level of deubiquitinating activity might be expected to perturb ubiquitin trimming and thus prevent efficient transfer of substrates to the proteasome. Indeed, ectopic over-expression of even wild-type ataxin-3 resulted in the accumulation of TCRa and CD3d [2, 3] , suggesting that this molecule is an important regulator of mammalian ERAD.
